127 results
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
, of the Compensation of our Named Executive Officers in 2023
Majority of the votes cast
Abstentions and broker non-votes will not be taken into account … Accounting Firm for the 2024 Fiscal Year
Majority of the votes cast
Abstentions and broker non-votes will not be taken into account in determining
8-K
EX-99.1
e13bv7vk 1unaym
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
EX-1.1
qelkxrtb0bw7temiok1
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
h6picbbwpmfqy3 u5
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
2hu wlalvkj
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
3ofno
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
tva4sne 5v
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
6niimhiq
14 Aug 23
Other Events
8:00am
8-K
EX-99.2
iwa c6f31ndsjyl
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
a5rly7wra
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm
8-K
EX-99.2
4h951sxoik6i8
15 May 23
Results of Operations and Financial Condition
7:05am